Difference between revisions of "Non-small cell lung cancer, MET-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s...")
 
m (regimen/variant)
Line 15: Line 15:
 
=Metastatic disease=
 
=Metastatic disease=
  
==Capmatinib {{#subobject:#791280|Regimen=1}}==
+
==Capmatinib {{#subobject:791280|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-

Revision as of 20:43, 6 May 2020

Section editor
TravisOsterman.jpg
Travis Osterman, DO, MS
Vanderbilt University
Nashville, TN

Social-twitter-icon.pngTravisOsterman
LinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

3 regimens on this page
3 variants on this page


Metastatic disease

Capmatinib

back to top

Regimen

FDA-recommended dose
Study Years of enrollment Evidence
Wolf et al. 2019 (GEOMETRY mono-1) Phase II

Biomarker Eligibility Criteria

  • Biomarker: MET exon 14 skipping

Chemotherapy

Continued indefinitely

References

  1. GEOMETRY mono-1: Juergen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan F. Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Rebecca Suk Heist. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. link to abstract contains verified protocol DOI